Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology

  • Received : 2018.03.11
  • Accepted : 2018.05.27
  • Published : 2019.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Osteonecrosis of the jaw (ONJ) is a well-known pathological condition in oncology derived from the use of bisphosphonates (BPs) and denosumab. Many molecular and immunological targets have been introduced for daily use in cancer treatment in recent years; consequently, new cases of ONJ have been reported in association with these drugs, especially if administered with BPs and denosumab. When the drugs are administered alone, ONJ is rarely seen. The objective of our study was to analyze the recent literature relative to the association of ONJ with these new drugs highlighting the pathogenic, clinical and therapeutic aspects. The close collaboration between maxillofacial surgeon, oncologist, dentist, and dental hygienist remains the most important aspect for the prevention, prompt recognition, and treatment of this pathology.

Keywords

References

  1. Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY. Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab 2015;22:151-65. https://doi.org/10.11005/jbm.2015.22.4.151
  2. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006;407:597-612. https://doi.org/10.1016/S0076-6879(05)07047-3
  3. Sun J, Sun Q, Brown MF, Dudgeon C, Chandler J, Xu X, et al. The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA. PLoS One 2012;7:e43158. https://doi.org/10.1371/journal.pone.0043158
  4. Ayllon J, Launay-Vacher V, Medioni J, Cros C, Spano JP, Oudard S. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol 2009;20:600-1. https://doi.org/10.1093/annonc/mdn788
  5. Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 2012;107:1665-71. https://doi.org/10.1038/bjc.2012.385
  6. Bozas G, Roy A, Ramasamy V, Maraveyas A. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib. Onkologie 2010;33:321-3. https://doi.org/10.1159/000313680
  7. Hoefert S, Eufinger H. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:463-9. https://doi.org/10.1016/j.tripleo.2010.04.049
  8. Agrillo A, Nastro Siniscalchi E, Facchini A, Filiaci F, Ungari C. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports. Eur Rev Med Pharmacol Sci 2012;16:952-7.
  9. van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O, Willems L, et al. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 2018;26:869-78. https://doi.org/10.1007/s00520-017-3903-5
  10. Koch FP, Walter C, Hansen T, Jager E, Wagner W. Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg 2011;15:63-6. https://doi.org/10.1007/s10006-010-0224-y
  11. Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:e1-3. https://doi.org/10.1016/S2212-4403(11)00692-4
  12. Garuti F, Camelli V, Spinardi L, Bucci L, Trevisani F. Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. Tumori 2016;102(Suppl 2):S69-70. https://doi.org/10.5301/tj.5000504
  13. Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F. Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg 2013;71:1532-40. https://doi.org/10.1016/j.joms.2013.03.019
  14. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938-42. https://doi.org/10.1126/science.289.5486.1938
  15. Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 2003;17:1713-21. https://doi.org/10.1038/sj.leu.2403071
  16. Viviano M, Rossi M, Cocca S. A rare case of osteonecrosis of the jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg 2017;43:120-4. https://doi.org/10.5125/jkaoms.2017.43.2.120
  17. Abel Mahedi Mohamed H, Nielsen CEN, Schiodt M. Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol 2018;125:157-63. https://doi.org/10.1016/j.oooo.2017.10.010
  18. Shen G, Ren H, Qiu T, Zhang Z, Zhao W, Yu X, et al. Mammalian target of rapamycin as a therapeutic target in osteoporosis. J Cell Physiol 2018;233:3929-44. https://doi.org/10.1002/jcp.26161
  19. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 2010;1804:433-9. https://doi.org/10.1016/j.bbapap.2009.12.001
  20. Indo Y, Takeshita S, Ishii KA, Hoshii T, Aburatani H, Hirao A, et al. Metabolic regulation of osteoclast differentiation and function. J Bone Miner Res 2013;28:2392-9. https://doi.org/10.1002/jbmr.1976
  21. Simone V, Ciavarella S, Brunetti O, Savonarola A, Cives M, Tucci M, et al. Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. BMC Cancer 2015;15:692. https://doi.org/10.1186/s12885-015-1717-8
  22. Kim DW, Jung YS, Park HS, Jung HD. Osteonecrosis of the jaw related to everolimus: a case report. Br J Oral Maxillofac Surg 2013;51:e302-4. https://doi.org/10.1016/j.bjoms.2013.09.008
  23. Yamamoto D, Tsubota Y, Utsunomiya T, Sueoka N, Ueda A, Endo K, et al. Osteonecrosis of the jaw associated with everolimus: a case report. Mol Clin Oncol 2017;6:255-7. https://doi.org/10.3892/mco.2016.1100
  24. Giancola F, Campisi G, Lo Russo L, Muzio LL, Di Fede O. Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report? Ann Stomatol (Roma) 2013;4(Suppl 2):20-1.
  25. Nifosi AF, Nifosi L, Nifosi G. Osteonecrosis of the jaw in a patient treated with denosumab and temsirolimus. SAJ Case Rep 2017;4:401.
  26. Rajabi M, Mousa SA. The role of angiogenesis in cancer treatment. Biomedicines 2017;5:E34. https://doi.org/10.3390/biomedicines5020034
  27. Magremanne M, Lahon M, De Ceulaer J, Reychler H. Unusual bevacizumab-related complication of an oral infection. J Oral Maxillofac Surg 2013;71:53-5. https://doi.org/10.1016/j.joms.2012.03.022
  28. Hartl DM, Bahleda R, Hollebecque A, Bosq J, Massard C, Soria JC. Bevacizumab-induced laryngeal necrosis. Ann Oncol 2012;23:276-8. https://doi.org/10.1093/annonc/mdr515
  29. Mailliez A, Baldini C, Van JT, Servent V, Mallet Y, Bonneterre J. Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. Br J Cancer 2010;103:772-5. https://doi.org/10.1038/sj.bjc.6605828
  30. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008;26:4037-8. https://doi.org/10.1200/JCO.2007.15.5424
  31. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumabassociated osteonecrosis of the jaw. Ann Oncol 2008;19:2091-2. https://doi.org/10.1093/annonc/mdn653
  32. Serra E, Paolantonio M, Spoto G, Mastrangelo F, Tete S, Dolci M. Bevacizumab-related osteneocrosis of the jaw. Int J Immunopathol Pharmacol 2009;22:1121-3. https://doi.org/10.1177/039463200902200429
  33. Wynn RL. Bevacizumab (Avastin): an anti-angiogenic drug associated with osteonecrosis of the jaw. Gen Dent 2011;59:410-3.
  34. Disel U, Besen AA, Ozyilkan O, Er E, Canpolat T. A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit. Oral Oncol 2012;48:e2-3. https://doi.org/10.1016/j.oraloncology.2011.07.030
  35. Katsenos S, Christophylakis C, Psathakis K. Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab. Arch Bronconeumol 2012;48:187-220. https://doi.org/10.1016/j.arbres.2011.08.004
  36. Pakosch D, Papadimas D, Munding J, Kawa D, Kriwalsky MS. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofac Surg 2013;17:303-6. https://doi.org/10.1007/s10006-012-0379-9
  37. Brunamonti Binello P, Bandelloni R, Labanca M, Buffoli B, Rezzani R, Rodella LF. Osteonecrosis of the jaws and bevacizumab therapy: a case report. Int J Immunopathol Pharmacol 2012;25:789-91. https://doi.org/10.1177/039463201202500328
  38. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009;76:209-11. https://doi.org/10.1159/000201931
  39. Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009;27:221-6. https://doi.org/10.1080/07357900802208608
  40. Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010;122:181-8. https://doi.org/10.1007/s10549-010-0866-3
  41. McArthur HL, Estilo C, Huryn J, Williams T, Fornier M, Traina TA, et al. Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol 2008;26(15 Suppl):9588. https://doi.org/10.1200/jco.2008.26.15_suppl.9588
  42. Francini F, Pascucci A, Francini E, Miano ST, Bargagli G, Ruggiero G, et al. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab. J Am Dent Assoc 2011;142:506-13. https://doi.org/10.14219/jada.archive.2011.0220
  43. Hopp RN, Pucci J, Santos-Silva AR, Jorge J. Osteonecrosis after administration of intravitreous bevacizumab. J Oral Maxillofac Surg 2012;70:632-5. https://doi.org/10.1016/j.joms.2011.02.104
  44. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-70. https://doi.org/10.1073/pnas.93.25.14765
  45. Bettini G, Blandamura S, Saia G, Bedogni A. Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process. BMJ Case Rep 2012;2012:bcr2012007284.
  46. Santos-Silva AR, Belizario Rosa GA, Castro Junior Gd, Dias RB, Prado Ribeiro AC, Brandao TB. Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:e32-6.
  47. Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009;9:263-71. https://doi.org/10.1517/14712590802666397
  48. Mawardi H, Enzinger P, McCleary N, Manon R, Villa A, Treister N, et al. Osteonecrosis of the jaw associated with ziv-aflibercept. J Gastrointest Oncol 2016;7:E81-7.
  49. Ponzetti A, Pinta F, Spadi R, Mecca C, Fanchini L, Zanini M, et al. Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. Tumori 2016;102(Suppl 2):S74-7. https://doi.org/10.5301/tj.5000405
  50. Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 2007;7:1245-56. https://doi.org/10.1517/14712598.7.8.1245
  51. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9. https://doi.org/10.1038/46303
  52. Owosho AA, Scordo M, Yom SK, Randazzo J, Chapman PB, Huryn JM, et al. Osteonecrosis of the jaw a new complication related to Ipilimumab. Oral Oncol 2015;51:e100-1. https://doi.org/10.1016/j.oraloncology.2015.08.014
  53. Hujoel P, Barasch A, Cunha-Cruz J, Curro FA, Sung AH, Vena D, et al. Osteonecrosis of the jaw and oral hygiene: a case-control study from Condor Dental PBRN. J Dent Hyg 2012;86:32-3.
  54. Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc 2011;77:b147.
  55. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al.; International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30:3-23. https://doi.org/10.1002/jbmr.2405

Cited by

  1. Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective vol.20, pp.11, 2020, https://doi.org/10.1080/14712598.2020.1790522
  2. Repurposing denosumab in breast cancer beyond prevention of skeletal related events: Could nonclinical data be translated into clinical practice? vol.13, pp.11, 2019, https://doi.org/10.1080/17512433.2020.1839416
  3. The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn vol.20, pp.2, 2019, https://doi.org/10.1080/14740338.2021.1861246
  4. Antiresorptive medication in oncology: the clinical and dental profile of patients in a reference center vol.47, pp.1, 2019, https://doi.org/10.5125/jkaoms.2021.47.1.20
  5. Cancer Patients at Risk for Medication-Related Osteonecrosis of the Jaw. A Case and Control Study Analyzing Predictors of MRONJ Onset vol.10, pp.20, 2019, https://doi.org/10.3390/jcm10204762